Fig. 4: Ibrutinib-dependent and Ibrutinib-independent repartition of H3K4me3 peaks.
From: Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
a Cis-elements enriched for the H3K4me3 mark were screened for the presence of validated binding sites for transcription factors and co-regulators (ReMap database). For each protein of the database, data were expressed as a score calculated using the highlighted equation allowing comparison between N1 and an average of N1–3, R1–2 samples before treatment. Scatter diagrams representing a comparison between REMI’s scores for samples (b) N1, (c) N2, (d) N3, (e) R1 and (f) R2 and reference profile N1 at 0 day, with time points before treatment in grey triangles, at 56 days in orange rectangles and at 1 or 7 days in blue circles. Details of the calculated scores are presented in Supplementary Table 5
